In this issue of Blood, Rijal et al have identified the inositol polyphosphate 4-phosphatase II (INPP4B) as a poor prognostic marker in acute myeloid leukemia (AML), driving chemoresistance through a novel gain-of-function mechanism independent of its phosphatase functions.
1
A lthough there has been no therapeutic breakthrough for the treatment of AML over the last 20 years, the cytogenetic and molecular characterization of this disease has allowed stratifying of risk groups with very different prognoses in terms of disease-free and overall survival (OS), and has identified relevant therapeutic targets currently under investigation, such as Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), IDH1/2, or epigenetic regulators. 2, 3 Furthermore, the analysis of residual disease following chemotherapy also helps to stratify postremission therapy. Thus, do we need another new prognostic marker to manage our patients? The answer is "yes" if this marker predicts early response to chemotherapy (ie, primary induction failure), and more importantly, if this new marker is linked to chemoresistance. Rijal et al investigated the expression profile of several phosphatases involved in the phosphoinositide-3 kinase (PI3K) pathway and found that INPP4B can fill in these 2 requirements.
Class I PI3K that produces the D3-phosphoinositide second messenger phosphatidylinositol 3,4,5-trisphosphate in response to membrane receptor activation plays a critical role in cell proliferation, survival, metabolism, and motility. These lipid kinases and the phosphatases regulating the level of D3-phosphoinositides have been an intense area of research in the field of cancer for the past 2 decades. 4 Most AML display a constitutive activation of the PI3K pathway that contributes to cell proliferation and chemoresistance. 5 has been shown to be a negative regulator of the PI3K pathway, it could play a different role in AML. Next, using ectopically INPP4B overexpression in low-expressing or specific INPP4B depletion in high-expressing AML cells, they provided evidence that INPP4B is an important player in the resistance to drugs used in the management of AML (cytarabine, daunorubicin, and etoposide). They judiciously used a catalytically inactive mutant of INPP4B (INPP4B-C842A) and unexpectedly, showed that it also mediated chemoresistance. Thus, these results demonstrated that INPP4B mediates chemoresistance through a novel gainof-function mechanism independent of its phosphatase activity in AML. Lastly, they validated in vivo the role of both INPP4B and INPP4B-C842A overexpression using xenografts in immunocompromised mice.
The first question we generally ask over such clinical results concerns its reproducibility in validation cohorts. Interestingly, other investigators very recently reported a similar clinical impact of INPP4B overexpression through the analysis of several publicly available AML datasets, strengthening the findings of Rijal et al. 6 Higher induction failure was also observed in this study, which is of particular interest with respect to our limited ability to predict resistance based on routinely available pretreatment covariates. 7 However, further studies are needed to address several issues raised by this study: (1) 
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In this issue of Blood, Stonestrom et al describe the unanticipated complexity of the distinct yet overlapping activities of acetyl-lysine-binding bromodomain and extraterminal motif (BET) proteins bromodomain-containing 2-4 (BRD2-4) in erythropoiesis, in the context of rising interests in BET pharmacologic inhibitors. 1 E pigenetic modifications dictate chromatin structure and affect gene expression. It has been long established that aberrant activity of the enzymes controlling the deposition, recognition, and removal of these chromatin marks often leads to cancer. Indeed, since
